{"id":"clindamycin-topical-gel-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Dryness or peeling"},{"rate":null,"effect":"Erythema or irritation"},{"rate":null,"effect":"Oiliness or folliculitis"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that penetrates sebaceous follicles and suppresses Cutibacterium acnes (formerly Propionibacterium acnes), the primary bacterium involved in acne pathogenesis. By inhibiting bacterial protein synthesis, it reduces bacterial colonization and associated inflammatory mediators. The topical formulation delivers high local concentrations to affected skin while minimizing systemic exposure.","oneSentence":"Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby reducing acne-causing bacteria and decreasing inflammation in acne lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:18.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris (topical treatment)"},{"name":"Bacterial skin infections (secondary indication)"}]},"trialDetails":[{"nctId":"NCT07392047","phase":"PHASE4","title":"Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-02","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT04469075","phase":"PHASE2","title":"Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-07-09","conditions":"Glioblastoma, Recurrent Glioblastoma, Skin Toxicity","enrollment":48},{"nctId":"NCT01044264","phase":"NA","title":"Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2007-12","conditions":"Acne Vulgaris","enrollment":602},{"nctId":"NCT05926869","phase":"PHASE2","title":"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT01874860","phase":"PHASE2","title":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-08","conditions":"Colorectal Cancer, Head and Neck Cancer","enrollment":24},{"nctId":"NCT01138514","phase":"PHASE3","title":"Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":1555},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT04584840","phase":"NA","title":"Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers","status":"UNKNOWN","sponsor":"Fundació d'investigació Sanitària de les Illes Balears","startDate":"2020-11-01","conditions":"Osteonecrosis of the Jaw, Bisphosphonate Induced, Osteonecrosis of the Jaw, Bisphosphonate Related","enrollment":50},{"nctId":"NCT03522441","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Akorn, Inc.","startDate":"2018-04-27","conditions":"Acne Vulgaris","enrollment":1125},{"nctId":"NCT02616614","phase":"PHASE3","title":"Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-05","conditions":"Acne Vulgaris","enrollment":862},{"nctId":"NCT03257202","phase":"PHASE2","title":"Topical Treatment and Prevalence of P. Acnes","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2017-09-11","conditions":"Surgical Site Infection","enrollment":12},{"nctId":"NCT04134273","phase":"PHASE1","title":"Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2019-03-20","conditions":"Acne Vulgaris","enrollment":1260},{"nctId":"NCT03883269","phase":"PHASE4","title":"Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-03-20","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT02731105","phase":"PHASE4","title":"Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-02","conditions":"Acne Vulgaris","enrollment":22},{"nctId":"NCT01047189","phase":"PHASE4","title":"Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT01445301","phase":"PHASE3","title":"Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-27","conditions":"Acne Vulgaris","enrollment":800},{"nctId":"NCT02058628","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-21","conditions":"Acne Vulgaris","enrollment":222},{"nctId":"NCT00757523","phase":"PHASE4","title":"Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-09-10","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT02465632","phase":"PHASE3","title":"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":1100},{"nctId":"NCT01132443","phase":"PHASE1","title":"W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-05-06","conditions":"Acne Vulgaris","enrollment":72},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT00689117","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-04","conditions":"Acne Vulgaris, Acne","enrollment":1649},{"nctId":"NCT00891982","phase":"PHASE3","title":"A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04-01","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT02595034","phase":"PHASE1","title":"A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-01","conditions":"Acne Vulgaris","enrollment":1000},{"nctId":"NCT01015638","phase":"PHASE4","title":"Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":36},{"nctId":"NCT00887484","phase":"PHASE4","title":"A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT00964223","phase":"PHASE4","title":"A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":28},{"nctId":"NCT00926367","phase":"PHASE4","title":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT01400932","phase":"PHASE3","title":"Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07","conditions":"Acne Vulgaris","enrollment":360},{"nctId":"NCT01769664","phase":"PHASE1","title":"A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2012-09","conditions":"Acne Vulgaris","enrollment":650},{"nctId":"NCT01788384","phase":"PHASE3","title":"Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris","status":"COMPLETED","sponsor":"Watson Laboratories, Inc.","startDate":"2012-07","conditions":"Acne Vulgaris","enrollment":708},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT01206348","phase":"PHASE4","title":"Combination Treatment for Moderate to Severe Acne","status":"COMPLETED","sponsor":"Medicis Global Service Corporation","startDate":"2010-09","conditions":"Acne","enrollment":97},{"nctId":"NCT00219570","phase":"PHASE4","title":"Dalacin-T Gel Post Approval Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-01","conditions":"Acne Vulgaris","enrollment":134},{"nctId":"NCT01052246","phase":"NA","title":"Pulsed Dye Laser Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Laserklinik Karlsruhe","startDate":"2008-10","conditions":"Acne Vulgaris","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Clindamycin Topical Gel 1%","genericName":"Clindamycin Topical Gel 1%","companyName":"Jinnah Postgraduate Medical Centre","companyId":"jinnah-postgraduate-medical-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby reducing acne-causing bacteria and decreasing inflammation in acne lesions. Used for Acne vulgaris (topical treatment), Bacterial skin infections (secondary indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}